These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 27909081)

  • 1. Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study.
    Jones G; Wallace T; McIntosh MJ; Brockwell L; Gómez-Reino JJ; Sebba A
    J Rheumatol; 2017 Feb; 44(2):142-146. PubMed ID: 27909081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Burmester GR; Rigby WF; van Vollenhoven RF; Kay J; Rubbert-Roth A; Blanco R; Kadva A; Dimonaco S
    Ann Rheum Dis; 2017 Jul; 76(7):1279-1284. PubMed ID: 28389552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.
    Jones G; Sebba A; Gu J; Lowenstein MB; Calvo A; Gomez-Reino JJ; Siri DA; Tomsic M; Alecock E; Woodworth T; Genovese MC
    Ann Rheum Dis; 2010 Jan; 69(1):88-96. PubMed ID: 19297346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
    Ishiguro N; Atsumi T; Harigai M; Mimori T; Nishimoto N; Sumida T; Takeuchi T; Tanaka Y; Nakasone A; Takagi N; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):217-226. PubMed ID: 27414105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
    Mori S; Yoshitama T; Abe Y; Hidaka T; Hirakata N; Aoyagi K; Ueki Y
    Rheumatology (Oxford); 2019 Jul; 58(7):1274-1284. PubMed ID: 30793749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study.
    Drobinski PJ; Bay-Jensen AC; Karsdal MA; Sardar S; Siebuhr AS
    Arthritis Res Ther; 2021 Jan; 23(1):13. PubMed ID: 33413588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S; Yamakawa R;
    Mod Rheumatol; 2019 Sep; 29(5):767-774. PubMed ID: 30299202
    [No Abstract]   [Full Text] [Related]  

  • 12. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis.
    Jones G
    Expert Rev Clin Immunol; 2010 Mar; 6(2):189-95. PubMed ID: 20402381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study.
    Pablos JL; Navarro F; Blanco FJ; Román-Ivorra JA; Alonso A; Martín Mola E; Cantalejo M; Ercole L; Rivero N;
    Clin Exp Rheumatol; 2019; 37(3):437-444. PubMed ID: 30299241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
    Kivitz A; Olech E; Borofsky MA; Zazueta B; Navarro-Sarabia F; Radominski SC; Merrill JT; Pacheco-Tena C; Pei J; Nasmyth-Miller C; Pope JE
    J Rheumatol; 2018 Apr; 45(4):456-464. PubMed ID: 29247149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF; Qushmaq K; Aljishi F
    Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
    Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
    J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.
    Safy-Khan M; Jacobs JWG; de Hair MJH; Welsing PMJ; Edwardes MD; Teitsma XM; Luder Y; Devenport J; van Laar JM; Pethoe-Schramm A; Bijlsma JWJ
    Ann Rheum Dis; 2020 Apr; 79(4):460-463. PubMed ID: 32033935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).
    Kaneko Y; Kato M; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T;
    Ann Rheum Dis; 2018 Sep; 77(9):1268-1275. PubMed ID: 29853455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.